Health economics research demonstrates the cost saving impact of the device
The device facilitates better-targeted medication which leads to lower medicine consumption and shorter hospital stay by patients.
This project activity is lead by Magda Rosenmoller
IESE Business School, University of Navarra, Barcelona
Expert level summary
During phase 1 of this activity, the objective is to provide business concept activities, health economics and regulatory frameworks through cost-effectiveness studies. Upon completing studies of third party data, hospitals can then move onto phase 2 of the study, which will require them to capture first-party data to supplement the initial findings. Bringing together data from the first two phases is essential for validating the workflow and patient pathway efficiency claims, as well as helping create robust business development and planning activities.
Detailed activity description
To provide business concept activities, health economics and regulatory frameworks, the regulatory investigation is subcontracted with the RFP preparation and post report review managed by IESE Business School in coordination with NG Biotech’s regulatory affairs management.
The Phase 1 cost-effectiveness and health economics study includes 3rd party data, published data, a literature review and interviews. This serves as a basis to design the subsequent phases of the study, which require partner hospitals to capture 1st party data to use in the study.
The continuation of the cost-effectiveness and health economics study utilises partner hospitals to capture first-party data that can be used to validate the workflow and patient pathway efficiency claims.
Business development and planning activities, including validation of value proposition with customers and stakeholders.
Bringing together the work done on cost-effectiveness, health economics and business planning activities in order to complete a Health Technology Assessment report. A dialogue with EUnetHTA begins and validates the report and findings, in parallel with a reimbursement review.
